AgomAb Therapeutics Updates Articles and Expands Authorized Capital Structure

AgomAb Therapeutics NV ADR ( (AGMB) ) has shared an update.

On March 5, 2026, AgomAb Therapeutics NV, a Belgian life sciences company, reported to the U.S. Securities and Exchange Commission the adoption of amended and restated articles of association following an extraordinary general shareholders’ meeting held on January 15, 2026. The updated charter, formalized by notarial deeds on February 9 and March 4, 2026, confirms the company’s status as a Belgian NV, its Antwerp registered office, and its broad corporate purpose spanning therapeutic research, product commercialization, and related financial and corporate activities.

The revisions set the company’s fully paid-up share capital at €302,993,346.72 divided into 49,219,746 ordinary shares and grant the board authority for five years to double that capital through various instruments, including new shares, convertible bonds, and warrants, with the power to restrict or cancel preemptive rights. This expanded authorized capital and flexible securities framework strengthen AgomAb’s ability to raise funding, structure equity-linked incentives, and pursue strategic growth or partnerships, potentially enhancing its financial agility and positioning within the biotechnology and pharmaceutical sectors.

The most recent analyst rating on (AGMB) stock is a Buy with a $28.00 price target. To see the full list of analyst forecasts on AgomAb Therapeutics NV ADR stock, see the AGMB Stock Forecast page.

More about AgomAb Therapeutics NV ADR

AgomAb Therapeutics NV is a Belgian life sciences company focused on scientific research, clinical studies, and development of biological, chemical, and natural products with therapeutic or diagnostic potential, primarily in pharmaceutical, medical, chemical, and veterinary sectors. The company’s corporate object also covers worldwide distribution of its products and related services, as well as broader financial, licensing, and investment activities to support its operations and growth in the healthcare and biotechnology markets.

Headquartered in Antwerp in the Flemish Region, AgomAb operates as a limited liability company (NV/SA) with the ability to establish offices and branches in Belgium and abroad, and to participate in or finance other companies. Its capital structure allows it to issue various securities, manage intellectual property such as patents and trademarks, and engage in industrial, financial, and commercial activities aligned with its life sciences focus.

Average Trading Volume: 303,110

Current Market Cap: $367K

For an in-depth examination of AGMB stock, go to TipRanks’ Overview page.